 |
 Video: What is a Stock Split?
|
|
|
| Immatics is a holding company. Through its subsidiaries, Co. is engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer patients. Co.'s focus is the generation of therapeutic options for solid tumor patients. Co. is developing its targeted immunotherapy product candidates via two treatment modalities: Adoptive Cell Therapies (ACT) and antibody-like Bispecifics. Co.'s clinical product class ACTengine is based on genetically modifying a patient's own T cells to express a proprietary TCR. Co.'s TCR Bispecifics are consisting of a portion of the TCR that recognizes cancer cells and a T cell recruiter domain that recruits and activates T cells. According to our Immatics stock split history records, Immatics has had 0 splits. | |
|
Immatics (IMTX) has 0 splits in our Immatics stock split history database.
Looking at the Immatics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Immatics shares, starting with a $10,000 purchase of IMTX, presented on a split-history-adjusted basis factoring in the complete Immatics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/13/2018 |
|
| End date: |
05/02/2024 |
|
| Start price/share: |
$9.60 |
|
| End price/share: |
$10.89 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
13.44% |
|
| Average Annual Total Return: |
2.37% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$11,344.71 |
|
| Years: |
5.39 |
|
|
|
|
|
